Brief: Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results
02/11/2023 11:20
Nov 2 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES POSITIVE TOP-LINE IBEZAPOLSTAT PHASE 2
EFFICACY
RESULTS WITH 96% CLINICAL CURE RATE IN PATIENTS WITH C.
DIFFICILE INFECTION
* ACURX PHARMACEUTICALS INC - MEETS PROTOCOL PRIMARY
OBJECTIVE OF
ASSESSING PRIMARY EFFICACY ENDPOINT OF CLINICAL CURE RATE AFTER
10 DAYS OF ORAL TREATMENT
* ACURX PHARMACEUTICALS INC - IBEZAPOLSTAT WAS WELL
TOLERATED; NO
DRUG-RELATED SERIOUS ADVERSE EVENTS
* ACURX PHARMACEUTICALS INC - PREPARATION UNDERWAY FOR
END-OF-PHASE 2 FDA MEETING AND ADVANCEMENT TO PHASE 3
* ACURX PHARMACEUTICALS INC - IBEZAPOLSTAT HAS PREVIOUSLY
RECEIVED
FDA QUALIFIED INFECTIOUS DISEASE PRODUCT AND FAST-TRACK
DESIGNATION
Source text for Eikon: ID:nPn3N7RhVa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln